GASTROINTESTINAL DRUGS ADVISORY COMMITTEE

June 27, 2000

Slides

Lotronex

Lotronex, Richard Kent MD, Glaxo Wellcome   ppt   html

IBS Burden of Illness, Ian M Gralnek MD MSHS, UCLA   ppt   html

Safety & Efficacy of Alosetron, Allen Mangel MD PhD, Glaxo Wellcome   ppt   html

Risk Management Plan, Elizabeth B Andrews PhD MPH, Glaxo Wellcome   ppt   html

Risk Management Program Communication Plan, J S Hull, Glaxo Wellcome   ppt   html

Conclusion, Richard Kent MD, Glaxo Wellcome   ppt   html

Benefit-Risk Reevaluation of Marketed Drugs, Victor F C Raczkowski MD MS, FDA   ppt   html

Lotronex Summary of Issues, Victor F C Raczkowski MD MS, FDA   ppt   html

Risk-Management Options, Victor F C Raczkowski MD MS, FDA   ppt   html

Lotronex, Hugo E Gallo-Torres MD PhD, FDA   ppt   html

Medical Guides, Nancy M Ostrove PhD, FDA   ppt   html

Postmarketing Drug safety and risk Intervention Studies, Evelyn M Rodriguez MD MPH, FDA   ppt   html